Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook!
The role of sulfasalazine in pure axial spondyloarthritis (axial SpA) is claimed to be almost non-existent, due to very low-quality evidence from available literature. Guidelines recommend early institution of biologic therapy if one fails 2 NSAIDs sequentially in optimal doses over 4 weeks. As NSAI...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=5;spage=57;epage=63;aulast=Shankar |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544043145363456 |
|---|---|
| author | Subramanian Shankar Arun Hegde |
| author_facet | Subramanian Shankar Arun Hegde |
| author_sort | Subramanian Shankar |
| collection | DOAJ |
| description | The role of sulfasalazine in pure axial spondyloarthritis (axial SpA) is claimed to be almost non-existent, due to very low-quality evidence from available literature. Guidelines recommend early institution of biologic therapy if one fails 2 NSAIDs sequentially in optimal doses over 4 weeks. As NSAIDs are effective in about 70% cases, the remaining 30% patients would require biologics within the first few weeks of onset of illness. With each passing year, a significant percentage of the remaining patients would require biologics due to NSAID failure. Relapse rates after discontinuation of TNFα inhibitors at 1-year followup is almost 100%, implying lifelong therapy with biologics. Cochrane metaanalysis reveals that ASAS 40 response (40% improvement in pain, function, and inflammation) is in the range of 25%-40% for various biologics over 24 weeks. Considering that in a country with a per Capita GDP of just Rs 1.44 lakhs/ year, where 80% of people have to meet their medical expenses out of pocket and the cheapest anti TNFs cost over Rs 2 lakhs per annum, the western guidelines are clearly impractical in Indian context. In this review article, we present a contrarian view on the use of Sulfasalazine in axial SpA. We look at the available data on Sulphasalazine with a different perspective and arrive at different conclusions. We also explore the role of other innovative strategies in the management of axial SpA and suggest alternate algorithms catering to the Indian scenario. |
| format | Article |
| id | doaj-art-2a214025396b4f4f89b5a1e1e7d78215 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-2a214025396b4f4f89b5a1e1e7d782152025-02-03T11:07:26ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012020-01-01155576310.4103/0973-3698.284743Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook!Subramanian ShankarArun HegdeThe role of sulfasalazine in pure axial spondyloarthritis (axial SpA) is claimed to be almost non-existent, due to very low-quality evidence from available literature. Guidelines recommend early institution of biologic therapy if one fails 2 NSAIDs sequentially in optimal doses over 4 weeks. As NSAIDs are effective in about 70% cases, the remaining 30% patients would require biologics within the first few weeks of onset of illness. With each passing year, a significant percentage of the remaining patients would require biologics due to NSAID failure. Relapse rates after discontinuation of TNFα inhibitors at 1-year followup is almost 100%, implying lifelong therapy with biologics. Cochrane metaanalysis reveals that ASAS 40 response (40% improvement in pain, function, and inflammation) is in the range of 25%-40% for various biologics over 24 weeks. Considering that in a country with a per Capita GDP of just Rs 1.44 lakhs/ year, where 80% of people have to meet their medical expenses out of pocket and the cheapest anti TNFs cost over Rs 2 lakhs per annum, the western guidelines are clearly impractical in Indian context. In this review article, we present a contrarian view on the use of Sulfasalazine in axial SpA. We look at the available data on Sulphasalazine with a different perspective and arrive at different conclusions. We also explore the role of other innovative strategies in the management of axial SpA and suggest alternate algorithms catering to the Indian scenario.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=5;spage=57;epage=63;aulast=Shankaraxial spondyloarthritiscost effectiveinnovative strategiessulphasalazine |
| spellingShingle | Subramanian Shankar Arun Hegde Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! Indian Journal of Rheumatology axial spondyloarthritis cost effective innovative strategies sulphasalazine |
| title | Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! |
| title_full | Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! |
| title_fullStr | Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! |
| title_full_unstemmed | Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! |
| title_short | Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! |
| title_sort | sulfasalzine in the management of pure axial spondyloarthritis need to have a relook |
| topic | axial spondyloarthritis cost effective innovative strategies sulphasalazine |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=5;spage=57;epage=63;aulast=Shankar |
| work_keys_str_mv | AT subramanianshankar sulfasalzineinthemanagementofpureaxialspondyloarthritisneedtohavearelook AT arunhegde sulfasalzineinthemanagementofpureaxialspondyloarthritisneedtohavearelook |